Mitosis-Specific Negative Regulation of EGF-receptor in Breast Cancer: Molecular Mechanisms, Biological Significance and Therapeutic Application
Abstract
This project is to study the mechanisms of regulation of the EGFR during the cell cycle, in breast epithelial cells. Especially how cell which overexpress EGFR can overcome the negative regulation. We plan to use this negative regulation of the EGFR during the M phase of the cell cycle to develop a novel therapeutic strategy that uses the combination of EGF-PE and taxol as treatment. In trying to elucidate the mechanism of action of EGFR we have shown that cdc2 which can physically associate with neu, cannot associate with EGFR. Also we have shown that in vitro with treatment of EGF-PE and taxol together we do see that EGFR overexpressing cells are selectively killed, i.e. normal cells are protected from the EGF-PE by taxol treatment This novel approach may be a potential therapeutic strategy to treat breast cancer patients in the future. In addition to our proposed work we have discovered that cyclin Dl which is unregulated by EGFR can also be up regulated by beta-catenin. This work while not directly related to this proposal does help in understanding EGFR signaling pathways. Also this is a very novel finding of the correlation of the unregulation of beta-catenin and breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2000
- Accession Number
- ADA387089
Entities
People
- Stephanie M. Miller
Organizations
- University of Texas at Austin